Yahoo
NasdaqCM - Delayed Quote USD

Achieve Life Sciences, Inc. (ACHV)

8.31 -0.17 (-2.00%)
At close: September 3 at 4:00:01 PM EDT
8.31 0.00 (0.00%)
After hours: September 3 at 7:30:06 PM EDT
Trade ACHV on Coinbase
Chart Range Bar
Loading chart for ACHV
Chart does not reflect overnight price.
  • Previous Close 8.48
  • Open 8.50
  • Bid 6.07 x 100
  • Ask 10.58 x 100
  • Day's Range 8.20 - 8.53
  • 52 Week Range 2.62 - 8.61
  • Volume 1,532,430
  • Avg. Volume 1,805,730
  • Market Cap (intraday) 855.12M
  • Beta (5Y Monthly) 2.23
  • PE Ratio (TTM) --
  • EPS (TTM) -1.63
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 13.83

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

www.achievelifesciences.com

28

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ACHV
67.20%
S&P 500 (^GSPC)
13.18%

1-Year Return

ACHV
190.56%
S&P 500 (^GSPC)
20.15%

3-Year Return

ACHV
60.42%
S&P 500 (^GSPC)
71.57%

5-Year Return

ACHV
1.07%
S&P 500 (^GSPC)
70.83%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -10.17M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

9.00
13.83 Average
8.31 Current
21.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst Morgan Stanley
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 13

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    848.95M

  • Enterprise Value

    676.59M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    64.03

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.21%

  • Return on Equity (ttm)

    -844.99%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -114.04M

  • Diluted EPS (ttm)

    -1.63

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    187.3M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    156.32M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

8.31 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: